ReviewHerz2020
Amyloid cardiomyopathy.
Review in Herz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.The international journal of cardiovascular imaging · 2025Review
- Management of Arrhythmias and Conduction Disorders in Amyloid Cardiomyopathy.Journal of clinical medicine · 2024Review
- Non-Cardiac Amyloidosis Findings Are Not Increased in African American Carriers ofJournal of personalized medicine · 2024Article
- Preclinical evaluation of Tc-99m p5+14 peptide for SPECT detection of cardiac amyloidosis.PloS one · 2024Article
- Arrhythmias in Patients with Cardiac Amyloidosis: A Comprehensive Review on Clinical Management and Devices.Journal of cardiovascular development and disease · 2023Review
- Cardiac Amyloidosis with Discordant QRS Voltage between Frontal and Precordial Leads.Medicina (Kaunas, Lithuania) · 2021Article
- Cardiac amyloidosis with overt multiple myeloma presenting with pulmonary effusion: case report.Journal of surgical case reports · 2021Article
- Narrative review of pharmacotherapy for transthyretin cardiac amyloid.Annals of translational medicine · 2021Review
- Cardiac amyloidosis-A review of current literature for the practicing physician.Clinical cardiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis is a heterogeneous group of diseases characterized by extracellular deposition of amyloid fibrils in many different organs finally resulting in organ failure. Cardiac involvement is common for immunoglobulin light chain amyloidosis (AL) or transthyretin amyloidosis (ATTR); the latter is caused by a transthyretin gene variant or wild-type protein. Precise diagnostic assessment including laboratory tests, electrocardiography, echocardiography, cardiac magnetic resonance imaging, biopsy, and/or bone scintigraphy is mandatory for definition of the amyloid type and finally for treatment initiation. Treatment of cardiac amyloidosis includes symptomatic therapy of heart failure as well as the underlying disease. Causative treatment of AL amyloidosis is according to regimens used for multiple myeloma. For many years, orthotopic liver transplantation was the only treatment available for hereditary ATTR amyloidosis, but important advances have been made after approval of a novel class of medication, namely, RNA silencers. However, currently no treatment is available to remove amyloid deposited in the tissue. Thus, early diagnosis is still critical to afford the best efficacy of available therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.